RxDoctor Payments Data

Vadim Azbel, MD

Psychiatry · Staten Island, NYNPI 1538187695

Payments from drug & device makers

$11,894in general payments, 2019–2025

Across 222 payments — averaging $53.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Vanda Pharmaceuticals Inc.$450
  • Alkermes, Inc.$394
  • Almatica Pharma LLC$370
  • Sunovion Pharmaceuticals Inc.$318
  • Takeda Pharmaceuticals U.S.A., Inc.$312
  • plus $2K from 12 others

What the payments were for

  • Speaking & faculty fees$7,15060%
  • Food & beverage$4,61239%
  • Education$1311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,894 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$383,051
Medicare patients
386
Services billed
4,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole100$155,121
NamzaricMemantine Hcl/Donepezil Hcl238$132,997
VraylarCariprazine Hcl66$91,792
TrintellixVortioxetine Hydrobromide147$67,399
LatudaLurasidone Hcl32$43,007
AmbienZolpidem Tartrate48$28,704
LunestaEszopiclone32$26,407
Memantine Hcl ErMemantine Hcl323$23,729
Doxepin Hcl193$20,871
Rivastigmine220$19,816
Lurasidone Hcl47$15,449
VascepaIcosapent Ethyl36$10,412
ProzacFluoxetine Hcl13$9,541
ExelonRivastigmine13$8,771
BelsomraSuvorexant18$7,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Vraylar, Viibryd$8,118$229,889319 claims
Otsuka America Pharmaceutical, Inc.Rexulti$301$155,121100 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$312$67,399147 claims
Sunovion Pharmaceuticals Inc.Latuda$318$43,00732 claims
Almatica Pharma LLCLoreev Xr, Sertraline Hcl$370$8,906541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →